Lux Biosciences Sponsors October 6 Fund Raising Event to Build Awareness and Help Support Research Against Serious Ophthalmic Diseases
Posted on: Thursday, 27 September 2007, 09:00 CDT
Serious eye diseases like uveitis, macular degeneration and dry eye syndrome threaten the eyesight and lower the quality of life for many thousands of people each year. To help raise awareness about these illnesses and support research aimed at fighting these important ophthalmic diseases, Lux Biosciences is sponsoring a fund raising event on Saturday October 6 to benefit the MERSI Walk for Vision and The Foundation for Fighting Blindness.
The event, to be held from noon to 3 pm on Sundial Field of Liberty State Park, Jersey City, NJ, will include music, games, food and drink, and a raffle. A donation of $35 for adults will include admission, food, beverage and a souvenir T-shirt. Admission for children under 12 will be $10 and will include food and beverage. Raffle tickets are available for $2 each.
"Recent scientific and medical advances are opening the door to a variety of potential new treatment options for serious ophthalmic diseases," said Ulrich Grau, Ph.D., president and chief executive of Lux Biosciences. "As a company actively engaged in the clinical development of several of these therapies, we are very pleased to support the activities of the MERSI Walk for Vision and The Foundation for Fighting Blindness as patient advocates and supporters of research within this important field of medicine."
About Lux Biosciences
Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company is currently enrolling patients in late stage clinical studies in two areas:
the LUMINATE pivotal clinical program investigating LX211, a next-generation calcineurin inhibitor, for the treatment of uveitis, and
the LUCIDA pivotal clinical program with LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye, for the prevention of corneal transplant rejection.
For more information on Lux Biosciences and information about participating in the company's clinical trials, please visit the company's website at www.luxbio.com. For more information about the October 6 fundraising event, contact Kathleen Campanile at Lux Biosciences, 201-705-5235.
Source: Business Wire
Related Articles
- Lux Biosciences' Investigational Therapy for Uveitis, Luveniq(TM), to Be Featured at 7th International Symposium on Uveitis
- Lux Biosciences Presents Preclinical Data Demonstrating Potential of LX214 As Best-in-Class Topical Treatment for Chronic Inflammatory Diseases of the Eye
- Lux Biosciences Completes Enrollment in LUMINATE Pivotal Trial Program for Novel Uveitis Therapy, LUVENIQ(TM)
- Lux Biosciences' Presentations at ARVO Highlight Both Topical and Polymer Delivery Technologies Targeting Chronic Inflammatory Ocular Diseases
- Lux Biosciences Reports on Pivotal Programs in Uveitis and Corneal Transplant Rejection at ARVO Meeting
- Lux Biosciences Eye Drug Set to Receive Orphan Designation
- Lux Biosciences' Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
- Lux Biosciences Initiates Clinical Trials of Its Second Pivotal Stage Program
- Isotechnika's Partner, Lux Biosciences, Receives Orphan Drug Designation for Ophthalmic Indications of ISA247
- Lux Biosciences Announces Exclusive Worldwide License Agreement With NIH for Late Stage Ophthalmic Product
 |
 |
User Comments (0)
RSS Feeds